Grass pollen allergoid. A 4-year follow-up study.

Area of Science:

• Allergy and Immunology
• Immunotherapy

Background:

• Grass pollen allergy affects a significant portion of the population.
• Subcutaneous immunotherapy (SCIT) is a common treatment for allergic diseases.
• Different allergen extract formulations may influence treatment efficacy.

Purpose of the Study:

• To compare the efficacy of an 'allergoid' extract versus a semi-depot extract for grass pollen allergy.
• To evaluate symptom scores, medication use, and immunological responses (IgG).
• To assess the long-term therapeutic effects of both treatments.

Main Methods:

• An open comparative study involving 31 patients with grass pollen allergy.
• Patients received either an 'allergoid' extract or a semi-depot extract.
• Data collected included symptom scores, drug consumption, and specific IgG antibody levels over time.

Main Results:

• The 'allergoid' group initially showed better outcomes in symptom reduction, decreased medication needs, and increased IgG response.
• These initial differences diminished in subsequent treatment years, with both groups achieving successful treatment.
• A significant correlation was observed between the total antigen dose administered and the IgG response.
• The allergoid group's superior initial results, potentially linked to a 4-fold higher antigen dose, suggest a possible long-term therapeutic advantage.

Conclusions:

• Both 'allergoid' and semi-depot allergen extracts are effective for treating grass pollen allergy.
• Higher antigen doses may be associated with a stronger IgG response and potentially better long-term clinical outcomes.
• Further research into optimal allergen dosing for immunotherapy is warranted.